Given that Siglec-15 has a function complementary to that of PD-1/PD-L1, therapeutic antibody targeting Siglec-15 (NC318) has been tested in a phase I trial for NSCLC patients refractory to PD-1 blockade (25). Here, CD274 is linked to non-small cell lung carcinoma.